Scholarlink

<p>Between March to December 2024, we observed a PEG-IFNα2a shortage in France for MPN patients. We identified and followed 90 patients from our center and observed 80% of difficulties obtaining the drug, and 61 patients among all (67.8%) did not receive their prescribed drug on time (impacted group). Twenty-one patients need to reduce the dosage of PEG-IFNα2a and 27 stopped the drug. Ten clinical events were identified with nine in the impacted group (<i>p</i>=0.04). No hematological or only partial responses were more frequent in the impacted group (<i>p</i>=0.01). The allelic burden variations were also studied during this period; 17 patients obtained a VAF &lt;10%. Eight patients stopped the drug because of VAF &lt;4% and remained with molecular response. Three-quarters of the patients experimented with psychological and financial impacts of shortage. This study is the first one to explore a shortage of cytoreductive drugs happened in MPN. Much informations will be helpful for clinicians.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Laura Cailly,
  • Wayne-Corentin Lambert,
  • Jean-Richard Eveillard,
  • Brigitte Pan-Petesch,
  • Laura Herbreteau,
  • Laetitia Rio,
  • Lanig Civi,
  • Adrian Tempescul,
  • Florence Dalbies,
  • Hussam Saad,
  • Cristina Bagacean,
  • Marie-Anne Couturier,
  • Gaelle Guillerm,
  • Eric Lippert,
  • Jean-Christophe Ianotto

摘要

Between March to December 2024, we observed a PEG-IFNα2a shortage in France for MPN patients. We identified and followed 90 patients from our center and observed 80% of difficulties obtaining the drug, and 61 patients among all (67.8%) did not receive their prescribed drug on time (impacted group). Twenty-one patients need to reduce the dosage of PEG-IFNα2a and 27 stopped the drug. Ten clinical events were identified with nine in the impacted group (p=0.04). No hematological or only partial responses were more frequent in the impacted group (p=0.01). The allelic burden variations were also studied during this period; 17 patients obtained a VAF <10%. Eight patients stopped the drug because of VAF <4% and remained with molecular response. Three-quarters of the patients experimented with psychological and financial impacts of shortage. This study is the first one to explore a shortage of cytoreductive drugs happened in MPN. Much informations will be helpful for clinicians.